Here's a look at some of the top legal news stories for medical device companies this week: Medtronic's new Ev3 unit pays $1.3m in whistleblower suit; Medtronic settles another whistleblower suit for $2.8m; Ex-NFL great Gault must face SEC fraud charges; Appeals court upholds Abiomed win in shareholders lawsuit; Pelvic mesh lawsuits: Boston Scientific wants 700 Philly cases sent to federal court
Studies of thrombectomy devices made by Medtronic's Covidien, Stryker and Penumbra show that they dramatically improve the likelihood that patients will recover from stroke.
(Reuters) - Grabbing and removing a clot blocking blood flow to the brain via thrombectomy, rather than just administering clot-busting drugs, dramatically improves the likelihood that patients will recover from a stroke, according to 2 highly-anticipated studies released today.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Medtronic's new Ev3 unit pays $1.3m in whistleblower suit; GPOs: Premier buys the rest of direct sourcer S2S Global; CareFusion crushes it in final quarter; BD beats Q1 estimates, raises outlook, shares jump; Zimmer revises Biomet bid for EU regulators
A labeling miscue prompts Covidien to recall 2 models of its Trellis clot-busting infusion device.
UPDATED Feb. 12, 2015, with new information from Medtronic.
Results from a study of Medtronic's ClosureFast varicose vein device, published this month in the British Journal of Surgery, show an 91.9% occlusion rate after 5 years.
Here's a look at some of the top regulatory stories for medical device companies this week: Regulators deal Wright Medical a double whammy; Medtronic wins FDA approval for Melody pulmonary valve; FDA approves Cohera's TissuGlu surgical sealant; FDA approves Medtronic's Pipeline Flex aneurysm device; Sorin wins MRI-safe pacemaker approval in Japan
Medtronic agrees to settle for $1.25 million a whistleblower lawsuit inherited from the Ev3 subsidiary it acquired in the $50 billion Covidien deal.